Health Catalyst Analyst Price Targets

Wall Street analyst price targets and consensus rating for Health Catalyst (HCAT).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

3Buy

8Hold

Consensus RatingOverweight# Analysts11Avg. Consensus PT$6Upside to Avg. PT+233.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 21, 2026	Canaccord Genuity	Richard Close	Downgrade	Buy→Hold	$3→$2
Aug 13, 2026	Wells Fargo	Stan Berenshteyn	PT Cut	Equal-Weight	$2→$2
Aug 11, 2026	Citigroup	Daniel Grosslight	PT Cut	Neutral	$3→$2
Jul 21, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$2→$3
Jun 26, 2026	Wells Fargo	Stan Berenshteyn	PT Raise	Equal-Weight	$1→$2
May 12, 2026	Stephens & Co.	Jeff Garro	PT Cut	Equal-Weight	$2→$2
May 11, 2026	Cantor Fitzgerald	Sarah James	Suspends	Neutral	—
Mar 18, 2026	Wells Fargo	Stan Berenshteyn	Downgrade	Overweight→Equal-Weight	$5→$1
Mar 13, 2026	Citigroup	Daniel Grosslight	PT Cut	Neutral	$3→$2
Mar 13, 2026	Canaccord Genuity	Richard Close	PT Cut	Buy	$5→$2
Mar 13, 2026	Stephens & Co.	Jeff Garro	PT Cut	Equal-Weight	$4→$2
Mar 13, 2026	Stifel	David Grossman	PT Cut	Hold	$4→$2
Mar 13, 2026	Cantor Fitzgerald	Sarah James	PT Cut	Neutral	$4→$3
Jan 9, 2026	Citigroup	Daniel Grosslight	PT Cut	Neutral	$3→$3
Nov 11, 2025	Citigroup	Daniel Grosslight	PT Cut	Neutral	$4→$3
Nov 11, 2025	Stifel	David Grossman	PT Cut	Hold	$5→$4
Nov 11, 2025	Wells Fargo	Stan Berenshteyn	PT Cut	Overweight	$6→$5
Oct 8, 2025	Evercore ISI Group	Elizabeth Anderson	PT Cut	In-Line	$4→$3
Oct 8, 2025	Keybanc	Scott Schoenhaus	PT Cut	Overweight	$5→$4
Oct 7, 2025	Cantor Fitzgerald	Sarah James	Maintained	Neutral	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.

Avi Kapoor

PRO
Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5

Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $1.75 to $1.5.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2

Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.5 to $2.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3

Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and raises the price target from $2 to $3.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Raises Price Target to $1.75

Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and raises the price target from $1 to $1.75.

Benzinga Newsdesk

Health Catalyst Inc

Health Catalyst Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PRO
Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5

PRO
Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2

PRO
Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Raises Price Target to $1.75

People Also Watch

People Also Watch

Health Catalyst Inc

Health Catalyst Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PROCanaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

PROWells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5

PROCitigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2

PROCanaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3

PROWells Fargo Maintains Equal-Weight on Health Catalyst, Raises Price Target to $1.75

People Also Watch

People Also Watch

PRO
Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5

PRO
Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2

PRO
Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3

PRO
Wells Fargo Maintains Equal-Weight on Health Catalyst, Raises Price Target to $1.75